Overview

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

Status:
Not yet recruiting
Trial end date:
2022-08-02
Target enrollment:
Participant gender:
Summary
The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel